Bristol-Myers Squibb has signed an agreement worth $475 million to develop a new form of cancer immunotherapy drug with US biotech Dragonfly Therapeutics.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.